This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


RIBOMIC, Inc.
【Field/Business】
Pharmaceutical/Drug Discovery
Pharmaceutical/Drug Discovery
Pharmaceutical/Drug Discovery
last update:2015/10/5
Profile

Delegates :
Yoshikazu Nakamura


Incorporated :
August  1 , 2003

Paid in Capital :
2892 Million yen  

Employees :
19 人

Address :
Shirokanedai Usui Build. Minato-ku. Shirokanedai 3-16-13 TOKYO
〒108-0071

TEL/FAX :
81-3-3440-3303 / 81-3-3440-3729

URL:
hppt://www/ribomic.com

Attachment :

Mission/Background :
RIBOMIC, Inc. is a biopharmaceutical company in Tokyo. The company is developing molecular targeting
pharmaceuticals using RNA aptamers with its unique and advanced platform technologies named " RiboART System"
The company's business model is composed two business. One is performing its own research projects and
licensing befor clinical study and other is co-developping with pharmaceutical company.

Technology & Business
RIBIMIC's RiboART (Ribomic Aptamer Refined Therapeutics) System is is a unique package on in-house state-of
- art technologies covering all the key pre-clinical steps: selection by various SELEX, initial validation
anlysis, processing of aptamer for optimazation, in-vitro cell-based assay, in vivo animal-model assey etc.

Collaboration : Otsuka Pharmaceuticals and Taisho Pharmaceuticals etc.
License : Fujimoto Pharmaceuticals
Products & Service
Products & Service Name
Stage
Outline
Milestone
RBM004
Preclinical
anti NGF aptamer for pain
to start clinical study
RBM007
Preclinical
ant FGF2 aptamer for borne disease, RA, AMD etc.
to start clinical study
RBM006
Preclinical
anti autotaxin aptamer for IPF etc.
to start clicical study








Highlights
1, to lisence RBM004 to Fujimoto Phaemaceduticals at April 2014.
1,to execution of research agreement with Taisho Pharmaceuticals at March, 2014
1,IPO to Tokyo Stock Exchange Mather's market.
1,to extend for one year on research agreement with Otsuka Pharmaceuticals re.RBM002 & 003 at Dec. 2014.
1,to move periostin aptamer to pre-clinical stage as own development project(RBM008) at January 2015.



Hot news
2015, 8,113 publication of finacial statement of 1st quarter of the fiscal year of 2015,

Alliance strategy
to license RBM007 and to collaborate with pharmaceutical company which would like to enter into aptamer drug development

 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.